of the current Phase I trial, and outline potential options for future investigation.
Pathophysiology and Existing Preclinical/Clinical Evidence
Initiated by the primary spinal cord trauma, the evolution of secondary injury mechanisms begins within seconds and continues for several weeks. 3, 13, 28 An important occurrence early on within this secondary injury cascade is the development of neuronal ionic imbalance, particularly increased intracellular sodium concentration, as a result of trauma-induced activation of voltage-sensitive sodium channels. 2, 33 The increased intracellular sodium concentration leads to a concomitant rise in intracellular calcium levels and also acts to stimulate intracellular acidosis and the development of cytotoxic edema. 16, 17, 23 The influx of sodium and calcium lead to an increased neuronal release of excitotoxic glutamate, resulting in excitotoxicity-mediated secondary injury and local cell death. 20, 30 One approach investigated to attenuate these specific injury events has been the delivery of pharmaceutical agents that block the constitutive neuronal sodium channel activation seen after SCI. A variety of sodium channel-blocking compounds, including locally administered tetrodotoxin, as well as systemically administered lidocaine and phenytoin, have been shown to preserve neural tissue as well as improve behavioral outcomes in several preclinical animal models of SCI. 1, 24, 31 In spite of these promising findings, none of these compounds have been subject to systematic evaluation in the context of human SCI.
Riluzole is a sodium channel-blocking benzothiazole anticonvulsant, which, like the agents described above, has demonstrated significant neuroprotective effects in preclinical SCI models (Fig. 1) . 27, 29 In a 2001 study by the Fehlings group, the effects of riluzole were compared with phenytoin, CNS5546A (a novel sodium channel-blocking compound), and a control compound in rats with severe compression-induced cervical SCI. 26 At 6 weeks' follow-up, while rats in all treatment groups demonstrated some degree of recovery, those in the riluzole treated group experienced a significantly larger degree of functional recovery as compared to the other treatment groups. Also in comparison to the other groups, the riluzole-treated animals exhibited a significantly reduced area of tissue cavitation at the injury epicenter on postmortem histological analysis. Riluzole's neuroprotective effects are due to its combined ability to prevent sodium and calcium influx as well as to block the synaptic release of excitotoxic glutamate. However, in light of the relative paucity of synaptic connections within the spinal cord white matter, the axon-sparing properties of riluzole are thought to be most related to its sodium channel-blocking actions.
In the clinical realm, although riluzole has not been studied extensively in the context of SCI, it has been widely used in the treatment of the neurodegenerative disorder ALS. 6, 7, 19, 32 A 2007 Cochrane review, summarizing the findings of 4 placebo controlled randomized trials, concluded that when given at a dosage of 100 mg daily, riluzole is safe and improves median tracheostomy-free survival by 2-3 months in patients with ALS. 21 Regarding adverse events, riluzole was well tolerated, with the exception that treated patients were 2.6 times more likely to experience an increase in serum alanine transaminase levels as compared with patients treated with placebo. 21 However, this effect was found to be uniformly reversible with cessation of riluzole therapy and was only reported after several months of riluzole administration. In light of this favorable safety and efficacy profile, the FDA has approved riluzole for patients with ALS, with administration typically commenced at the time of diagnosis and continued chronically.
Given its documented efficacy in preclinical SCI studies, as well as its safety in a human ALS population, riluzole appears an attractive candidate for evaluation in human patients with SCI. Before proceeding with a comparative effectiveness study, however, it was felt prudent to first evaluate the safety and pharmacokinetic profile of this medication within an SCI-specific population.
Phase I Clinical Trial for Riluzole in Traumatic SCI

Study Objectives and Design
Beginning in the spring of 2010, a Phase I study was undertaken with the goal of developing the safety and pharmacokinetic profile of riluzole in patients with traumatic SCI. Secondary objectives were to compare neurological, functional, and pain outcomes of the enrolled participants to outcomes of patients from the NACTN prospective SCI registry, matched for injury and demographic characteristics. This trial was designed as a prospective, single-arm, open-label multicenter study with a target enrollment of 36 participants. The sample size was based on NACTN registry incidence rates of adverse events ranging from 0.15 to 0.30. Using a 1-sided exact binomial test with a Type I error rate of 5%, a case series of 36 is expected to have at least 80% power to detect a doubling of a complication rate.
The safety end point follow-up period for the study is 6 months. However, neurological, functional, and pain outcomes will continue to be assessed at 12 months postinjury.
Study Setting
The trial was undertaken by the North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury. NACTN is a collaborative network of 8 North American university-affiliated departments of neurosurgery, a data management center, and a pharmacological center (Table 1) .
The study protocol was reviewed and approved by the institutional review board of each participating site and by the US Army Medical Research and Materiel Command Office of Research Protections, Human Protection Office. This study is also listed in ClinicalTrials. gov, a service of the US National Institutes of Health.
Eligibility Criteria
Assessment of an individuals' study eligibility was made at hospital presentation by the site-specific princi-pal investigator or study coordinator according to the inclusion and exclusion criteria shown in Table 2 .
Intervention Details
Participants received riluzole 50 mg every 12 hours for a total of 14 days, with treatment initiated within 12 hours of injury. The 12-hour drug window, as well as the 2-week duration of therapy, was chosen based on a desire to match the period of drug administration to the known period of sodium-and glutamate-induced secondary injury after SCI (several minutes after injury until 2 weeks after injury). 22 Riluzole was administered either orally or enterally through a nasogastric tube. When given orally, a single 50-mg tablet was given; however, if a nasogastric route was required, the 50-mg tablet was crushed and then dispersed in water prior to administration. Although riluzole is well absorbed in the stomach and proximal intestine, coadministration of the drug with food can reduce absorption up to 20%. As a result, feeding, whether via an oral or nasogastric route, was not permitted within 2 hours before and was delayed until at least 1 hour after riluzole was given. Since riluzole undergoes hepatic metabolism, primarily by cytochrome P450 1A2, coadministration with other pharmacological agents metabolized by this enzyme (such as quinolone antibiotics, amitriptyline, or omeprazole) was prohibited to prevent variations in serum drug concentration.
Baseline Assessment
On patient admission to a study center, the site prin- cipal investigator or designee performed a neurological examination in accordance with the ASIA/International Medical Society of Paraplegia recommendations. 4 This examination established the baseline ASIA Impairment Scale grade, ASIA motor score, and ASIA sensory score. Additional clinical information, such as age, sex, Glasgow Coma Scale score, injury mechanism information, the time of injury, and medical history, were also assessed and recorded. All personnel performing neurological assessments underwent a 2-day training course in performing ASIA examinations. Also at the time of initial assessment, a comprehensive set of trauma blood work was obtained including a pregnancy test and a serum liver panel as detailed below.
Outcome Data and Follow-Up
Adverse Events. Throughout the course of this study, adverse events were carefully monitored for each participant. Particular care was made to track adverse events previously associated with riluzole administration in the ALS literature, particularly hepatotoxicity. Baseline blood work included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma glutamyl transpeptide, and bilirubin levels as well as prothrombin time and international normalized ratio. Liver enzyme tests were repeated on Days 3 and 14 after the start of riluzole. Data were recorded on a wide range of adverse events including infections, respiratory complications, cardiovascular events, deep vein thrombosis/pulmonary embolus, skin breakdown, and neuropathic pain. All serious adverse events were reported to the coordinating center and to the central medical monitor. There were no deaths among the 36 patients enrolled in the study.
Neurological, Functional, and Pain Outcome Assessment. The ASIA Impairment Scale grade, ASIA motor score, and ASIA sensory score are the primary neurological outcome measures used in this study. The Spinal Cord Independence Measure and Brief Pain Inventory short form were used to assess functional status and pain outcomes, respectively. 8, 12 Outcome measures are assessed at 6 weeks, 3 months, 6 months, and 1 year postinjury.
Follow-up data on adverse events as well as neurological, functional, and pain outcomes will be compared between enrolled riluzole-treated patients and non-riluzole-treated patients enrolled in the NACTN prospective SCI registry in the final study analysis.
Collection of Pharmacological Data. Blood samples for determining the peak and trough serum riluzole concentrations were drawn on Day 3 and Day 14 of riluzole administration for all participants. Complete details of pharmacological data collection and analysis can be 
Progress Made to Date and Future Directions
As of January 2012, the target enrollment of 36 participants has been achieved. Complete analysis of the trial data is underway, and we anticipate that the final results will be available in the summer of 2012. Assuming that the safety profile of riluzole in SCI patients is confirmed, we will use the findings of this study to plan a Phase II trial evaluating the effects of riluzole on long-term neurological and functional outcomes. To this end, data from the current Phase I trial will be used to determine an appropriate treatment effect size for future sample size calculations.
Conclusions
Initiated by the primary spinal cord trauma, a host of secondary pathological processes combine to expand the area of neurological tissue injury after SCI. As part of this process, posttraumatic constitutive activation of neuronal voltage-gated sodium channels leads to increased intracellular sodium and calcium concentrations with concomitant cellular swelling and increased release of excitotoxic glutamate. Riluzole, a sodium channel-blocking anticonvulsant drug, has shown efficacy in preclinical SCI studies and has proven safe and effective in the treatment of human patients with ALS. To initiate the translation of this therapy to the clinic for SCI patients, we have undertaken an open-label Phase I trial to define the safety and pharmacokinetic profile of riluzole in this population. We look forward to publishing the final results of this study later this year.
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